Modern methods of pathogenetic therapy of multiple sclerosis


如何引用文章

全文:

详细

In recent years there has been significant progress in the treatment of multiple sclerosis (MS). The article reviews current approaches to the pathogenetic treatment of multiple sclerosis. Authors consider the mechanism of action of drugs modulating disease course. The treatment regimens of the MS with glucocorticoids, interferon beta, glatiramere acetate, mitoksantron, natalizumab are presented. It is emphasized that the management of patients with MS requires an individual approach with the involvement of many specialists in various medical fields.

参考

  1. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;18(4):767-78.
  2. Brown KA. Factors modifying the migration of lymphocytes across the blood-brain barrier. Int. Immunopharmacol 2001;1:2043-62.
  3. Buckle GJ. Functional magnetic resonance imaging and multiple sclerosis: the evidence for neuronal plasticity. J. Neuroimaging 2005;15(Suppl. 4):82S-93S.
  4. Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci 2008;29(Suppl. 2):S253-255.
  5. Compston A. Mechanisms of axon-glial injury of the optic nerve. Eye 2004;18(11):1182-87.
  6. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17.
  7. Confavreux C, Vukusic S. Multiple sclerosis: a degenerative disease? Bull Acad Natl Med 2008;192(3):483-91.
  8. Dong C, Flavell RA. Cell fate decision: T-helper 1 and 2 subsets in immune responses. Arthritis Res 2000;2:179-88.
  9. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-37.
  10. Filippi M, Rocca MA. Cortical reorganisation in patients with MS. J Neurol Neurosurg Psychiatry 2004;75(8):1087-89.
  11. Filippi M, Rocca MA. Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Curr Opin Neurol 2003;16(3):275-82.
  12. Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;71(10):766-73.
  13. Hemmer B, Archelos JJ, Hartung H-P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301.
  14. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives [Invited review]. Brain 1997;120:865-916.
  15. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008;68(17):2445-68.
  16. Neuhaus O, Archelos JJ, Hartung H-P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. TRENDS Pharmacol Sci 2003;24(3):131-38.
  17. Neumann H, Cavalie A, Jenne D, et al. Induction of MHC class I genes in neurons. Science 1995;269:549-52.
  18. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(22):2387-89.
  19. Reddy H, Narayanan S, Arnoutelis R, et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 2000;123:2314-20.
  20. Rieckmann P, Maurer M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr Opin Neurol 2002;15:361-70.
  21. Rocca MA, Filippi M. Functional MRI in multiple sclerosis. J Neuroimaging 2007;17(Suppl. 1):36S-41S.
  22. Steinman L. Multiple sclerosis: a two-stage disease. Natl Immunol 2001;2:762-64.
  23. Trapp BD, Ransohoff RM, Fisher E, et al. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999;5:48-57.
  24. Wegner C, Filippi M, Korteweg T, et al. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol 2008;15(2):109-10.
  25. Wilkins A, Scolding N. Protecting axons in multiple sclerosis. Mult Scler 2008;14(8):1013-25.
  26. Yong VW. Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology 2002;59:802-08.
  27. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2283&mid=1085056570&magid=170

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2009
##common.cookie##